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Abstract
Background. Continuous renal replacement therapy
(CRRT) increasingly is being used to treat critically ill
patients with renal disease. CRRT removes waste
products but also nutrients. Our understanding of
trace element CRRT clearance has been limited by
poor assay sensitivity. The development of inductively
coupled plasma mass spectrometry (ICP–MS) allows
for the measurement of CRRT trace element removal.
Methods. Continuous venovenous haemodialysis
(CVVHD) transmembrane clearances of trace elements
and urea were assessed using a bovine blood-based
in vitro model using two different haemodialyser types.
These findings were validated in 10 critically ill adult
patients receiving continuous venovenous haemodiafil-
tration (CVVHDF). Calculated daily trace element loss
was compared with a typical dose of daily trace
element supplementation.
Results. The mean SD in vitro CVVHD transmem-
brane clearances (ml/min) for the polysulfone haemo-
dialyser were chromium 0.97 0.23, copper
0.47 0.18, manganese 4.6 3.6, selenium 1.2 0.63
and zinc 2.3 0.32 and for the cellulose diacetate
haemodialyser chromium 1.54 0.91, copper
0.21 0.07, manganese 7.8 4.1, selenium 0.76 0.39
and zinc 2.7 0.37. The in vivo CVVHDF transmem-
brane clearances (ml/min) were chromium 5.4 2.4,
copper 0.45 0.33, manganese 1.9 4.6, selenium
1.6 1.2, and zinc 4.0 1.3.
Conclusion. ICP–MS assays detected the five trace
elements in the effluent of CVVHDF patients. Trace
element CVVHD transmembrane clearance estimates
for our in vitro model were supported by the in vivo
CVVHDF findings. Calculated daily trace element loss
attributed to CVVHD and CVVHDF with dialysate
flow rates of 33.3ml/min is less than what is provided
in a daily dose of a trace element supplementation
product.
Keywords: continuous dialysis; continuous renal
replacement therapy; critically ill; haemodiafiltration;
nutrition; trace elements
Introduction
Acute renal failure (ARF) occurs in approximately
2–5% of hospitalized patients [1] and in 5–6% of
critically ill patients [2]. Critically ill ARF patients are
often treated with continuous renal replacement
therapy (CRRT). Although CRRT removes waste
products, it also removes beneficial medications and
nutrients. Limited information is available on CRRT
drug removal [3] but even less is known about nutrient
clearance during CRRT, particularly the CRRT
clearance of trace elements.
Available data on trace element abnormalities in
renal failure patients have been generally derived from
chronic renal failure patients. Extrapolation of these
data to ARF patients is difficult especially for patients
treated with CRRT. Information on optimal trace
element requirements in patients receiving CRRT is
scarce [4]. Bellomo [5] proposed that the recommended
dietary allowances (RDA) of all trace elements be
provided and Druml [6], in a CRRT nutrition review
suggested providing trace element supplementation
twice weekly. Currently, there is little evidence to
support either suggestion. Story et al. [7] reviewed the
potential loss of chromium, copper, manganese,
selenium and zinc in critically ill patients receiving
continuous venovenous haemofiltration (CVVH).
Chromium and copper were found in the ultrafiltrate
of CVVH patients. Critically ill patients had lower
blood concentrations of selenium and zinc whether or
not they were receiving CVVH when compared with
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normal healthy volunteers. Klein et al. [8] detected a
small amount of zinc in the effluent of both their
CVVH and continuous venovenous haemodialysis
(CVVHD) patients. The authors concluded that zinc
losses were not large enough to merit additional zinc
supplementation in patients treated with CRRT who
are receiving zinc in their parenteral nutrition. Berger
et al. [9] reported that copper, selenium and zinc were
found in the effluent during treatment with continu-
ous venovenous haemodiafiltration (CVVHDF). Their
most significant finding was that selenium was
removed by CVVHDF at two times the daily
supplementation.
Since Story et al. [7] published their findings, more
sensitive trace element assay techniques have been
developed. Inductively coupled plasma mass spectro-
metry (ICP–MS) can detect 90% of the periodic
table at the sub-nanogram per gram level [10].
Utilizing this assay, we conducted an in vitro CVVH
trace element clearance study [11]. Our findings
reported measurable quantities of chromium, copper,
manganese, selenium, and zinc in the ultrafiltrate of
this in vitro CRRT model. Trace element loss was
estimated using study-derived sieving coefficients (SC)
and normal trace element blood concentrations. Our
findings suggested that the removal rate of selenium by
CVVH was greater than typical supplementation.
These findings led us to further investigate the
potential in vivo loss of trace elements during other
forms of CRRT since the removal characteristics of
CVVHD or CVVHDF differ from CVVH. Further, we
wished to determine whether our in vitro CRRT
models were representative of trace element removal
in critically ill patients receiving CRRT. We began this
investigation by determining the transmembrane clear-
ance of selected trace elements with our in vitro
CVVHD model. We then followed up the in vitro
data; by determining trace element transmembrane
clearance in 10 critically ill patients treated with
CVVHDF and compared these findings to our
in vitro transmembrane clearance data.
Materials and methods
In vitro CVVHD
The trace element transmembrane clearance by common
CRRT techniques was assessed using an in vitro bovine blood
CRRT model developed in our laboratory [11–14]. The
CVVHD model used 500ml of pH regulated, continuously
stirred bovine blood anticoagulated with 3.8% sodium
citrate. This blood was placed in a 1 l Erlenmeyer flask
which was submerged in a 378C water bath.
Urea (Sigma, St. Louis, MO, USA lot #30K0221) was
added to the bovine blood as a control solute to yield initial
blood urea nitrogen (BUN) concentration of 75mg/dl.
B. Braun Diapact CRRT machines and B.Braun Diapact
CRRTTM tubing kits for the CRRT circuits were used with
two different haemodialysers. A high permeability polysul-
fone [Optiflux F-160NR, Fresenius, (Lexington, MA) surface
area 1.5m2, ultrafiltration coefficient (Kuf) 45ml/h/mmHg,
lot # 3BU341] and a high efficiency cellulose diacetate hollow
fibre [CA-HP 170, Baxter (Deerfield, IL, USA) SA 1.7m2
Kuf 7.9ml/h/mmHg, lot # E03J12]. After the extracorporeal
circuit was primed, the blood was recirculated through the
CRRT system for 20min to allow for coating of the tubing
and haemodialyser by blood proteins [15,16].
Dialysate was prepared by adding 240ml of
NormocarbTM sterile bicarbonate renal dialysis concentrate
(Dialysis Solutions, Inc. Richmond Hills, Ontario, Canada)
to a 3 l bag of sterile water (Abbott Laboratories, Chicago,
IL, USA) according to the manufacturer’s directions. Once
reconstituted, Normocarb dialysate contains sodium
140mEq/l, magnesium 1.5mEq/l, chloride 106.5mEq/l and
bicarbonate 35mEq/l. CVVHD was run in single-pass mode
with a dialysate flow rate (Qd) of 33.3ml/min. The
ultrafiltrate production rate (Quf) was set at zero. Blood
flow rate (Qb) was 200ml/min (Table 1) and no adjustments
in blood flow rate were necessary to maintain adequate
pressures within the CRRT circuit. This process was repeated
six times each with a new haemodialyser and tubing circuit
for each haemodialyser membrane type.
In Vivo CVVHDF
Ten adult critically ill patients receiving CVVHDF at the
University of Michigan Hospital, Ann Arbor, MI, USA were
enrolled from March–September 2004. The study patients
were identified using the daily CRRT roster maintained in
the dialysis unit of University Hospital. The study investiga-
tors obtained informed consent and complied with
University of Michigan standards including patient con-
fidentiality according to the Health Information Portability
and Accountability Act (HIPAA). The study was approved
by the Institutional Review Board of the University
of Michigan Medical School (IRBMED) (approval
# 2004–0193)
Investigators played no role in determining who received
CRRT or what nutritional regimens they received. At the
University of Michigan, CRRT is administered as CVVHDF
with a Qd of 33.3ml/min and sufficient ultrafiltrate produc-
tion to achieve or maintain euvolaemia. Typically, adult
Table 1. Trace element content of study liquids
Mean SD Chromium (ng/g) Copper (ng/g) Manganese (ng/g) Selenium (ng/g) Zinc (ng/g)
In vitro dialysate normocarb n¼ 12 0.86 0.90 4.5 2.2 0.95 0.75 2.02 1.2 38.9 12.3
Tap water n¼ 1 2.4 152.9 4.5 1.4 97.4
Distilled water n¼ 1 2.7 5.4 2.1 2.1 6.8
Saline (0.9%) n¼ 1 3.0 2.6 1.3 2.7 21.7
In Vivo dialysate n¼ 10 patients 0.08 0.17 2.0 1.9 ND 2.5 2.3 43.1 17.2
ND: the trace element was not detectable within the limit of the assay.
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patients receive CVVHDF using the same high permeability
polysulfone haemodialyser (Optiflux F-160NR) used in
our in vitro trial. Physicians could choose a smaller
alternative polysulfone haemodialyser (HF1000, Gambro,
Lakewood, CO, USA) with a surface area of 1.1m2 and a
Kuf of 37ml/h/mmHg.
Sample collection
All samples in the in vitro and in vivo studies were obtained in
the same manner. All samples were obtained using trace
metal-free stainless steel needles (Becton Dickinson
Laboratories, Franklin Lakes, NJ, USA). Blood samples
were drawn at the pre-haemodialyser port (A) and the
effluent/spent dialysate (EF) and dialysate (D) samples from
the effluent/spent dialysate and dialysate sampling ports of
the CRRT circuits, respectively. One set of samples was
obtained from each study patient or in vitro circuit. In vivo
samples were placed on ice immediately and transferred to
the laboratory at the University of Michigan, College of
Pharmacy. Each effluent and dialysate sample was split into
two separate Falcon tubes (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) which are free of trace metals.
Blood samples were transferred to Falcon tubes and
centrifuged at 3000 r.p.m for 30min. The plasma was
transferred by metal-free pipette to two Falcon tubes and
stored at 808C until time of assay.
Assay
For the in vitro study, BUN was assayed on a COBAS
Integra 400 plus (Roche Diagnostics, Indianapolis, IN,
USA). The lower limit of detection was 1.8mg/dl and the
coefficient of variability was <10%. Bovine and human
plasma samples (from the in vitro and in vivo experiments,
respectively) were analysed for chromium, copper, manga-
nese, selenium and zinc content at the University of Notre
Dame in South Bend, Indiana using ICP-MS. The analytical
technique was performed according to previously described
procedures [17–19] with slight modifications using a Vacuum
Generators elemental PlasmaQuad model PQ2 ICP-MS.
Frozen plasma samples (5ml) were thawed and transferred
in a pre-cleaned, pre-weighed Teflon bomb and the sample
weight was recorded for each sample. Each sample was
transferred from a vial to a Teflon bomb by either pouring or
with the aid of a clean plastic transfer pipette. Samples were
then digested in open beakers using doubly distilled
concentrated nitric acid (5ml) and hydrogen peroxide
(2ml). After the first digestion was completed a second
nitric acid digestion was performed. The second digestion
used beakers closed at 1008C for 12 h, to ensure complete
breakdown of the organic matrix. Two ml of HNO3 were
added to the dried mass followed by 40 drops of H2O2 in a
drop-wise method to avoid foaming. The analytes were taken
to 15ml in 2% nitric acid. Nanopure 18M cm water was
used for sample dilutions. Monitoring of any contaminants
from reagents and laboratory environment was done with a
procedural blank included with each batch.
Single element solutions (Inorganic Ventures, Lakewood,
NJ, USA) were used to prepare calibration and internal
standard solutions. Analyses were performed using an
external calibration procedure. Scandium (Sc), cobalt (Co),
gallium (Ga) and yttrium (Y) were used as internal standards
for matrix and instrument drift corrections. Procedural blank
was analysed to check for any contribution from the re-
agents and laboratory environment. The reference materials
SRM-8414 (bovine muscle) and SRM-1577b (bovine liver)
were digested and analysed to be identical to the unknown
for quality control purposes. The assay was able to detect
each trace element at the sub-ng/g level.
Calculations
Trace element loss was calculated by determining the
extraction coefficient (EC) and transmembrane clear-
ance of each element. Trace element and urea, in vitro
transmembrane clearance equations for continuous
haemodialysis were as follows:
EC ¼ EF=A
Continuous haemodialysis transmembrane
clearance ¼ EC  Qd
Trace element transmembrane clearance, in vivo
involved ultrafiltrate production so the following
equation was used:
Continuous haemodiafiltration
transmembrane clearance ¼ EC  ðQd þ QufÞ
A¼ solute concentration in plasma obtained from
the pre-haemodialyser port;
EF¼ solute concentration in effluent/spent dialysate
obtained from the effluent/spent dialysate port;
Quf¼ ultrafiltrate production rate;
Qd¼ dialysate flow rate;
Trace element loss (mg/day)¼ECmean trace
element plasma concentration total dialysate
volume/day.
Trace element transmembrane clearance was calcu-
lated using the above equations. This transmembrane
clearance data were used to calculate the projected
daily loss of each trace element. The transmembrane
clearance (ml/min) multiplied by the arterial plasma
concentration (ng/g) of each trace element by 24 h gave
us a calculated CRRT daily loss of each trace element.
This CRRT loss for each trace element was compared
with the amount supplied by a daily dose of 1ml a
common parenteral trace element supplement
MultitraceTM-5 (MTE-5) Concentrate (American
Regent Laboratories, Inc. Shirley, NY, USA)
(Table 2). The calculated daily CRRT loss of each
trace element was subtracted from the amount
provided for supplementation by the MTE-5
Concentrate to determine if loss from CVVHD or
CVVHDF was greater than current supplementation
provided by MTE-5 Concentrate.
Sample size and data analysis
Power analysis for the in vitro experiments indicated
that a sample size of six haemodialysers would detect
a 25% difference in trace element transmembrane
clearance between haemodialyser types assuming a
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10% standard deviation with a power of 0.9 and a
significance level of P< 0.05. The mean EC (with
corresponding transmembrane clearance values)
between the two types of haemodialysers for each
trace element were compared using ANOVA. Power
analysis for the in vivo portion of the study was not
conducted, but sample size was consistent with
previous CRRT trace element clearance studies [7–9].
Results
Trace element content of the liquids (in vivo dialysate,
normal saline, distilled water, Normocarb in vitro
dialysate and tap water as a control) used in the in vitro
experiment was assessed to determine a possible source
of additional trace elements that could confound our
findings (Table 1). The custom dialysate used in
patients is made by a commercial vendor for the
hospital. The in vivo dialysate had the highest
concentration of zinc (43.1 ng/g) with much lower
concentrations of the other elements present. The
Normocarb dialysate used in the in vitro experiments
had relatively higher concentrations of zinc (38.9 ng/g)
than the other trace elements. Overall the trace element
profiles were similar between the in vitro Normocarb
dialysate and in vivo hospital dialysate (Table 1).
In vitro CVVHD model
All experiments were conducted as outlined in the
methods and there were no circuit failures during
the in vitro continuous haemodialysis experiments. The
mean SD urea EC for the cellulose diacetate
haemodialyser was 0.87 0.21 and for the polysulfone
haemodialyser 0.98 0.07. Table 2 contains the EC
data for each trace element. The mean in vitro EC from
the cellulose diacetate haemodialyser tended to be
higher for chromium, manganese and zinc than with
the polysulfone haemodialyser but these differences
were not statistically significant. The polysulfone
haemodialyser had higher EC for copper and selenium
but only copper’s EC difference was statistically
significant from the cellulose diacetate haemodialyser
(P< 0.02).
Based on the mean EC derived from these in vitro
data, we predicted trace element transmembrane
clearance for each haemodialyser using the experi-
mental conditions (dialysate flow rate of 33.3ml/min
and no ultrafiltrate production). The amount of
predicted daily trace element CRRT loss, calculated
from the in vitro mean plasma trace element blood
concentration and in vitro CRRT transmembrane
clearance values appears in Table 2. The amount of
daily trace element supplementation provided by a
common, commercially available trace element pro-
duct (MTE-5, components shown in Table 2) was
subtracted from the calculated daily trace element loss
to determine if CVVHD at 33.3ml/min would result inT
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a net daily loss of any trace element even if conven-
tional trace element supplementation is given.
In vivo CVVHDF study
Adults who received CVVHDF were a diverse group.
Large differences in duration of CVVHDF,
patient weight, age and type of nutrition received
were apparent (Table 3). The mean SD Qb
was 173 25ml/min. The mean SD Qd was
34.2 2.7ml/min. The mean ultrafiltrate production
rate in these patients was 7.65 3.05ml/min to achieve
or maintain euvolaemia. All patients received anti-
coagulation with sodium citrate according to the
University of Michigan protocol [20]. Nine patients
received CVVHDF using the Optiflux F160 NR
hemodialyser and one patient (patient 5) received
treatment with a Prisma HF1000 hemodialyser.
The arterial plasma concentrations of the five trace
elements varied widely in our patients (Table 4).
Copper and zinc showed the most inter-patient
variability. The in vivo EC and trace element CRRT
transmembrane clearance data appear in Table 5.
Daily CRRT loss calculations indicate that very little
copper, manganese, selenium and zinc were removed
Table 3. CVVHDF patient demographics
Patient Sex Age (years) Weight (kg) Cause of
acute renal
failure
Reason for
CRRT
Days on
CRRT prior
to sample
Time on current
haemodialyser
prior to sample
Nutrition
1 F 59 140 Sepsis ARF 11 days 14 h 30min Enteral
2 F 57 64 ESRD Fluid overload 12 days 18 h Enteral
3 M 57 77 Hepato-renal Fluid overload 13 days 10 h 50min PN
4 M 35 37 ESRD Hypotensive 11 days 16 h Enteral
5 F 18 65 Sepsis Acidosis 4 days 35 h PN
6 M 34 110 Cardio-renal Fluid overload 14 h 20min 14 h 20min Enteral
7 M 70 90 Heart failure ARF 43 h 43 h none
8 M 52 84 ARF ARF 25 h 25 h Enteral
9 M 41 NR Sepsis ARF 6 months 27 h Enteral
10 F 54 55 Sepsis ARF 4 days 30 h Enteral
ARF: Acute renal failure; ESRD: End-stage renal disease; PN: Parenteral nutrition.
Table 4. Patient trace element (TE) plasma concentrations compared with in vitro experiment bovine plasma values
TE Arterial plasma concentrations Chromium ng/g Copper ng/g Manganese ng/g Selenium ng/g Zinc ng/g
Patient 1 37.9 693.7 1.9 99.2 563.9
Patient 2 31.7 1241.3 1.6 92.9 597.8
Patient 3 27.8 923.9 1.5 86.2 675.9
Patient 4 34.1 874.4 1.5 60.4 497.9
Patient 5 29.5 952.6 7.3 170.6 1344.8
Patient 6 32.9 2362.9 1.6 111.8 681.8
Patient 7 32.9 1701.9 18.7 109.8 1028.7
Patient 8 22.0 1085.7 0.6 88.5 586.4
Patient 9 35.1 133.7 0.7 50.4 371.3
Patient 10 36.0 337.3 3.3 92.9 535.1
Mean SD 32.0 4.6 1030.7 642.4 3.9 5.5 96.3 32.5 688.4 287.0
Range 22.0 37.9 133.7 1701.7 0.6 18.7 50.4 170.6 371.3 1344.8
Bovine plasma MeanSD 38.1 1.04 575.7 19.8 5.1 0.40 68.4 3.7 399.6 14.8
Table 5. In vivo experiments: trace element continuous venovenous haemodiafiltration (CVVHDF) calculations
Chromium Copper Manganese Selenium Zinc
Extraction coefficient 0.13 0.06 0.01 0.007 0.05 0.1 0.04 0.03 0.1 0.03
Clearance (ml/min) 5.4 2.4 0.45 0.33 1.9 4.6 1.6 1.2 4.0 1.3
Daily loss (mg) 0.0042 0.011 0.0002 0.0037 0.069
Daily MTE-5 supplement (mg) (1ml) 0.01 1.0 0.5 0.06 5.0
Net daily supplementation (mg) 0.0058 0.99 0.499 0.056 4.93
Projected percent of daily dose removed by CVVHDF 42% 1% 0.2% 6.7% 1.4%
Clearance: transmembrane clearance; Net daily supplementation: (trace element amount in a typical daily dose) (projected daily
CRRT loss).
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by CVVHDF. Indeed, manganese was not detectable
in the effluent of 8/10 patients. Selenium was not
detectable in the effluent of 2/10 patients, consequently
the calculated CVVHDF transmembrane clearance of
manganese and selenium was considered to be zero in
these patients. Substantially more chromium was
removed than other trace elements; however the daily
CVVHDF loss was less than half of what would be
supplemented with a daily dose of MTE-5 (Table 5).
Discussion
We were able to quantify the transmembrane clearance
of five trace elements in critically ill patients receiving
CVVHDF. The emergence of ICP-MS assay technol-
ogy has allowed for the measurement of trace elements
to the sub-ng/g level. Most of the previous studies of
trace element disposition in patients receiving CRRT
were conducted with less sensitive assays [21,22].
A later study by Berger used ICP-MS, but these
authors did not report manganese and chromium
values [23]. These more sensitive assays allow us to
better characterize trace element disposition in CRRT.
Our study patients came from many different
intensive care units in our hospital and consequently
were a heterogeneous population. Plasma serum
concentrations of trace elements likely differ between
different types of critically ill patients and otherwise
healthy individuals. Our one-time sampling strategy
provides a snapshot of the trace element transmem-
brane clearance in these ten patients, many of whom
were receiving CVVHDF for more than a week. Our
methodology used a single plasma sample, which, for
the purposes of calculating daily losses, we assumed
was representative of the plasma concentration for an
entire day. However, it is likely that critically ill
patients have variability in their trace element plasma
concentrations depending on underlying illness and
state of inflammation or infection.
The differences in patient characteristics may par-
tially explain the wide variety in observed trace element
profiles (Table 4). For instance, study patient 9 had the
lowest plasma copper, selenium and zinc concentra-
tions. This individual received CRRT for 6 months to
treat ARF resulting from trauma and severe burns
from a motor vehicle accident. This prolonged
hospitalization likely influenced his trace element
profile. Other study patients with disparate trace
element concentrations include study patient 8, who
was post-liver transplant from hepatitis and had
received one day of CRRT at the time of sampling.
This enterally fed individual had the lowest manganese
and chromium plasma concentrations. Study patient 6,
a 43-year-old male with congestive heart failure and
cardiomyopathy awaiting a heart transplant, had the
highest copper value at twice the population mean.
This patient also had the shortest duration (14 h) of
CVVHDF at the time of sampling. Lastly, study
patient 5 was an 18-year-old female with a recent bone
marrow transplant and acute renal failure attributed
to sepsis. This patient had an elevated serum zinc
concentration at approximately twice the population
mean and was receiving daily trace element supple-
mentation with MTE-5.
Comparison of in vitro and patient-derived trace
element transmembrane clearance values in the present
study indicates agreement between in vitro polysulfone
and in vivo polysulfone EC and transmembrane
clearance (Tables 2 and 5). The trace elements
chromium and zinc exhibited a statistically significant
difference in transmembrane clearance between in vitro
and in vivo investigations (P< 0.01). The larger in vivo
transmembrane clearances might be partially explained
by the fact that the in vitro study utilized only 33.3ml/
min of dialysate flow, while the CVVHDF patients
received 33.3ml/min of dialysate flow plus an addi-
tional 7.7 3.1ml/min of ultrafiltrate production
providing additional convective transmembrane clear-
ance. Although statistically significant, the amount of
chromium and zinc removed by CVVHDF was
substantially below what is typically supplemented.
These differences may also be explained by variations
in protein binding and tissue distribution in study
patients compared with the in vitro setting. In vitro
experiments were run with blood obtained from
healthy cows. Bovine blood could differ from critically
ill human blood in terms of trace element concentra-
tions and to the extent that these trace elements bind to
plasma proteins (and consequently, how available they
are to be removed by CRRT). Inflammation can
influence the expression of trace element containing
proteins in the plasma as well as free trace element
concentrations. Consequently, the fact that our
patients were critically ill but the bovine blood came
from otherwise healthy cattle, may account for some
differences between the in vivo and in vitro studies.
Table 4 lists the mean bovine plasma trace element
concentration values and the plasma trace element
values from each of the patients in the in vivo part of
the study. We observed a wide range of trace element
concentrations in critically ill patients. Nonetheless,
there are substantial trace element differences between
the critically ill human and the bovine plasma obtained
from otherwise healthy cattle. The extent of trace
element protein binding can be inferred from EC
values [24]. EC is an indirect measurement of plasma
protein binding. The in vitro polysulfone experiment
EC values were compared with the EC values obtained
in patients who also were treated with polysulfone
haemodialysers. The EC values for chromium and zinc
differed significantly between bovine and human
values. Calculations from our bovine blood-based
in vitro study suggested that only small amounts of
trace elements would be removed by CVVHD and our
in vivo study corroborated those projections. However,
there were large differences between trace element
plasma concentrations and EC values limiting the
predictive value of the in vitro bovine blood-based
model.
The in vitro portion of the study allowed us to
compare the performance of two common CRRT
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haemodialysers F-160NR (polysulfone) and the
CA-HP 170 (diacetate). The surface area between
these two haemodialysers is similar but the ultrafiltra-
tion coefficient differences indicate the polysulfone
haemodialyser is more permeable. For small solutes
like urea, there are unlikely to be differences in EC.
Indeed, the urea EC approached one for both
haemodialyser types and is consistent with previously
published data [21,22]. CRRT transmembrane clear-
ance differences between haemodialysers are com-
monly observed in most drug studies [21,23], as most
drugs have larger molecular weights than urea.
However, the present study did not find many trace
element EC differences between haemodialyser types.
This is likely due to the fact that trace elements are
highly protein bound and were minimally removed by
either haemodialyser type. Typically, if large trans-
membrane clearance differences are observed between
CRRT haemodialyser types, they are observed with
larger molecular weight substances [14,21].
Our in vitro calculations were substantiated by the
in vivo study, namely that supplementation with
standard doses of MTE-5 results in more than
enough trace elements to overcome the amount lost
by CVVHD. However, there were limitations to this
study. For the in vivo investigation of this study, we did
not quantify the loss of trace elements in the faeces,
urine or wounds of our patients. Table 3 indicates that
nine of the 10 study patients were receiving nutrition,
but not all study patients were receiving the same
standardized nutrition. Two patients received parent-
eral nutrition and the remaining seven patients were
fed a variety of enteral nutrition formulations during
CRRT therapies. Another potential limitation is that
our in vitro study employed CVVHD while our study
subjects received CVVHDF. This additional convec-
tive clearance could influence EC. Nonetheless, the
agreement between the reported patient derived and
in vitro transmembrane clearance demonstrate that this
in vitro bovine blood model can be used to generate
initial CRRT transmembrane clearance estimates.
While we did not directly measure non-CRRT trace
element losses, it appears that MTE-5 standard doses
are sufficient to replace CVVHDF losses. However,
whether the MTE-5 daily dose is the optimal dose has
been recently called into question. Angstwurm et al.
[25] recently reported that higher doses of selenium
resulted in improved mortality rates in critically ill
patients with septic shock.
Conclusion
Measuring five trace elements with a very sensitive
ICP–MS assay, our in vitro, bovine blood-based
CVVHD model demonstrated that these trace
elements could be cleared by CVVHD with high
or low permeability haemodialysers. Despite this
transmembrane clearance, we calculate that standard
trace element supplementation such as MTE-5 that is
used in parenteral nutrition would more than replace
the trace element CVVHD losses. Our follow-up
clinical study conducted in 10 critically ill patients
receiving CVVHDF validated this finding. Daily trace
element supplementation exceeds trace element losses
attributed to CVVHDF with a dialysate flow rate of
33.3ml/min.
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